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Background: Cancer is characterized by both a high mutation rate as well as high
rates of cell division and cell death. We postulate that these conditions will result in
the eventual mutational inactivation of genes not essential to the survival of the
cancer cell, while mutations in essential genes will be eliminated by natural selection
leaving molecular signatures of selection in genes required for survival and
reproduction. By looking for signatures of natural selection in the genomes of cancer
cells, it should therefore be possible to determine which genes have been essential
for the development of a particular cancer.
Methods: We provide a proof of principle test of this idea by applying a test of
neutrality (Nei-Gojobori Z-test of selection) to 139 cancer-related nucleotide
sequences obtained from GenBank representing 46 cancer-derived genes.
Results: Among cancer associated sequences, 10 genes showed molecular evidence
of selection. Of these 10 genes, four showed molecular evidence of selection in
non-cancer transcripts. Among non-cancer associated sequences, eight genes
showed molecular evidence of selection, with four of these also showing selection in
the cancer associated sequences.
Conclusions: These results provide preliminary evidence that the same genes may
experience different selection pressures within normal and cancer tissues. Application
of this technique could identify genes under unique selection pressure in cancer
tissues and thereby indicate possible targets for therapeutic intervention.Introduction
Cancer cell clones evolve over the lifespan a tumour [1-3]. The selective pressures driv-
ing this clonal evolution are myriad and may include microenvironmental factors,
immune system surveillance, competition with other cancer and somatic cells, and
selective killing of cancer cells by surgery, chemotherapy and radiation [2-9]. Two fea-
tures of cancer portend intense natural selection among cancer cells. The first is the
observation that cancer cells (at least in the later stages of growth) experience a high
rate of cell death [10]. The second is the greatly increased rate of mutations in cancer
cells [11-16]. For example, a recent large scale study identified mutations in 11% of
protein coding genes examined over 756 cancer cell lines [17]. Many of these muta-
tions, even if they change the resulting protein sequence of the gene product may be© 2012 Ovens and Naugler; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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are of no significance to the cancer cell [3,12]. Indeed mutations in non-essential genes
may even be adaptive to the cancer cell as they shed costly metabolic processes irrele-
vant to reproduction of the cancer cell [3].
The high mutation rate and rapid cellular turnover may be expected to form an
intense environment for natural selection where mutations arise and are tested for
functional importance through competition with other cells. Eventually, this environ-
ment may lead to the situation where many genes have been rendered nonfunctional
by mutations and the subset of genes that have been important for the survival and
multiplication of the cancer cells will have been preserved through constant selection
of functional versions of these genes.
Evolutionary biologists have identified a number of methods for detecting molecular
evidence of natural selection [18]. These, so-called “tests of selection” attempt to differ-
entiate neutral evolution (i.e. genetic drift) from Darwinian selection. One commonly
used method compares ratios of synonymous and non-synonymous base substitutions.
This approach has the advantage of being robust with regards to population growth
[18], a confounding factor particularly important in the context of cancer cell growth.
Synonymous base substitutions change the exonic base pair sequence but conserve the
translated amino acid sequence (because of the degenerate nature of the DNA code).
In contrast, nonsynonymous base pair substitutions change both the base pair sequence
as well as the translated amino acid sequence. An increased rate of synonymous to
nonsynonymous base substitutions provides evidence that the base sequence in ques-
tion is or has been under natural selection to conserve the amino acid sequence (puri-
fying selection). Less commonly, a sequence may exhibit an increased rate of
nonsynonymous to synonymous base substitutions, indicating the base sequence in
question has been under natural selection to change the ancestral amino acid sequence
(diversifying selection). Perhaps the best described example of this is the diversifying
selection shaping the peptide binding grooves of MHC class I molecules [19]. We
might expect that the majority of selection pressures on cancer cells would be in the
form of purifying selection to maintain the function of essential genes. However it is
also possible that diversifying selection also plays a role in cancer cell evolution,
possibly in facilitating the exploitation of new microenvironments.
Here we test the hypothesis that due to the high mutation rates and increased cell
turnover in cancer cells, genes of importance to the survival of the cancer cell should
show molecular evidence of natural selection. Furthermore, we predict that in the
majority of cases this selection would be in the form of purifying selection.Materials and methods
As an initial test of this hypothesis we obtained cancer-derived DNA sequences from
GenBank using the search parameters “carcinoma expression library", "cancer-associated
transcript”, "tumour-associated transcript" and “Homo sapiens”. We did not attempt to
obtain an exhaustive list of all available transcripts but rather sought a convenience
sample of different genes where at least two different examples of the same gene sequence
from cancer tissue could be obtained. We did not include animal model-derived
sequences or experimental cell line sequences. To determine if these genes show natural
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of the same genes. In cases where we could not locate two non-cancer sequences from
among the GenBank entries, we isolated the relevant sequences from the NCBI reference
sequences primary and alternate assemblies. The sequences used in this study are all pub-
lically available from NCBI; the sequence references are given in Table 1.
Analyses were performed using the Molecular Evolutionary Genetics Analysis
(MEGA) software Version 5 [20]. Following sequence alignment using the ClustalW
method, the Nei-Gojobori Z-Test of Selection [21] was used to calculate the synony-
mous to nonsynonymous base substitution rates and the associated statistical proba-
bilities. P-values of less than 0.05 were considered significant.Results
A total of 46 cancer-derived genes represented by 139 sequences were identified
(Table 1). No sequences were derived from propagated cell lines. However, we were un-
able to determine what proportion of examples were from primary tumors vs meta-
static tumors. Of the 46 genes, nine genes showed evidence of purifying selection and 1
showed evidence of diversifying selection (Table 1). Six genes showed molecular evi-
dence of selection only in cancer associated sequences (all in the form of purifying se-
lection), four genes showed evidence of selection only in non-cancer associated
sequences (three cases of purifying selection and one case of diversifying selection),
and finally four genes showed molecular evidence of selection in both cancer and non-
cancer associated sequences (three cases of purifying selection and one case of diversi-
fying selection; Table 1). Table 1 also gives the GenBank accession numbers for all
sequences used as well as sequence divergence estimates (p-distances) and the results
of the Nei-Gojobori Z-tests of selection.
If signatures of selection become more common as mutations accumulate in a
cancer-associated sequence, we might expect to see greater nucleotide divergence esti-
mates in examples showing significant selection. To test this, we compared p-distances
in the 10 examples showing molecular evidence of selection in the cancer associated
sequences with the 36 examples not showing evidence of selection in the cancer asso-
ciated sequences. The mean p-distance of sequences showing evidence of selection was
0.125, while the mean p-distance of sequences not showing evidence of selection was
0.082 (unpaired t-test, p=0.398).Discussion
We describe a proof of principle test of a method of identifying molecular signatures of
natural selection in cancer-derived gene sequences. We also show that in a sample of
46 genes the cancer and non-cancer derived sequences show different patterns of
selection.
As a cancer grows and evolves and different genes come under selection pressure,
natural selection may be expected to record evidence of this selection in the proportion
of synonymous to nonsynonymous base substitutions as we have discussed here. Even
if that particular gene later becomes non-functional through further mutations, evi-
dence of prior selection pressure would be expected to persist. Thus a list of genes
showing molecular evidence of selection only in cancer cells could be considered to be





























0.603 none 0.290 GI:229892268
GI:229892301
GI:229892299





0.771 none 0.550 GI:19924155
GI:19924154





0.088 none 0.054 GI:386365498
GI:385648248
GI:385648249





0.234 none 0.090 GI:342187210
GI:342187198
GI:342187192




0.214 none 0.037 GI:223941893
GI:223941875






0.794 none 0.045 NC_000001.10
AC_000133.1












0.077 none 0.000 GI:331284154
GI:331284152
GI:331284159



































0.899 none 0.015 NC_000023.10
AC_000155.1






0.470 none 0.007 NC_000011.9
AC_000143.1















0.451 none 0.003 GI:333805638
GI:118918414






0.806 none 0.005 GI:189571676
GI:189571678





0.878 none 0.032 GI:40317615
GI:40317617
GI:40317619
0.353 none Involved in down-regulation





0.244 none 0.007 GI:134053863
GI:134053924
GI:134053890
0.002 purifying tumor-associated antigen
IRAK3 GI:34785939
GI:46854383
0.791 none 0.003 GI:216547518
GI:216547503




0.255 none 0.015 GI:288915537
GI:288915538


































0.211 none 0.162 GI:211938416
GI:310750386
GI:310750384
1.000 none possibly involved in






0.070 none 0.006 GI:32528292
GI:32528290






0.452 none 0.008 GI:296923778
GI:296923775







0.085 none 0.001 GI:182765463
GI:260166611
1.000 none involved in the production








0.197 none 0.151 GI:21040248
GI:341915375
GI:343183384
0.586 none delivers activating




0.337 none 0.011 GI:284004909
GI:257796251
GI:257796250
0.0151 purifying tumor-associated antigen
CSF1 GI:18088910
GI:166235151
0.413 none 0.142 GI:347360911
GI:166235149
GI:384475524
0.657 none cytokine that controls the
production, differentiation,





0.278 none 0.084 NC_000013.10AC_000145.1 0.320 none involved in regulating aneuploidy,




0.085 none 0.389 GI:324120957
GI:324120955
0.716 none adhesion and anti-adhesion




























0.736 none 0.008 GI:291167774
GI:145701029
GI:291167776
1.000 none serine protease;




0.090 none 0.005 GI:166064049
GI:166064053
GI:166064055














0.807 none 0.012 NC_000006.11
AC_000138.1




0.298 none 0.002 NC_000016.9
AC_000148.1
1.000 none epithelial membrane protein
TGM6 GI:33331029
GI:33331031
1.00 none 0.000 NC_000020.10
AC_000152.1







0.359 none 0.504 GI:33869357
GI:111120332




0.04 diversifying 0.524 GI:229577210
GI:13097164






0.012 purifying 0.220 GI:236460384
GI:236464355





0.012 purifying 0.097 GI:82571721
GI:34784984


































0.048 purifying 0.055 GI:374253795
GI:374253793














0.016 purifying 0.007 GI:164697166
GI:34528462
GI:336455029














0.009 purifying 0.072 GI37694064
GI:37694063
GI:158254733




0.002 purifying 0.186 GI:85397251
GI:85397957
GI:60116922











0.005 purifying tumor-associated antigen






















Ovens and Naugler Theoretical Biology and Medical Modelling 2012, 9:44 Page 9 of 11
http://www.tbiomed.com/content/9/1/44those genes which have been important to the survival of the cancer cell up to that
point on time. In essence, this provides us with a method to determine which genes
have been integral to the survival the cancer cell.
There are several potential weaknesses to our study. First, a different number of
sequences were available for the various genes we examined. With a greater number of
sequences we may expect a greater power to detect signatures of selection. To test such
an effect we compared the mean number of sequences from genes which showed selec-
tion (3.17) to the mean number of sequences from genes which did not show selection
(3.27). The difference was not statistically significant (p=0.134, unpaired t-test). There-
fore, although this is a potential theoretical concern, we can find no evidence of this in
our data.
Second, we do not have information about the geographic or racial origins of the
individuals from whom the cancer and non-cancer gene sequences were derived. It is
possible that increased variability noted for some genes could be due to these factors.
Third and perhaps most importantly, the choice of the model to calculate dN/dS as
well as the test interpretation are both potentially controversial. The Nei-Gojobori
method is perhaps less conservative than a maximum likelihood model but at the same
time if the majority of sites in a protein evolve under purifying selection (as we might
expect in a functionally essential gene in a tumour) the dN/dS statistic has reduced
sensitivity to detect positive selection [22]. Moreover, the behaviour of dN/dS statistics
when applied to polymorphisms within a population may behave differently than when
applied to fixed mutations between species [23]. Whether cancer cells from the same
tumour and/or from tumours from different individuals are sufficiently diverged to be
considered analogous to different species [24] is a critical unanswered question. There-
fore, because of these uncertainties, we decided to use the simple Nei-Gojobori statistic
for this preliminary analysis. As major cancer sequencing initiatives begin producing
whole genome sequences from paired cancer/normal samples from the same patient,
this question will become more important. Further work should critically examine the
optimal statistic to be used for these analyses.
Although we could not detect a statistically significant difference in the mean p-
distances between cancer associated sequences showing evidence of selection and those
that did not, there was a trend toward greater p-distances among the sequences show-
ing selection and so our inability to demonstrate a difference may be a factor of the
limited sample size.
Parenthetically, the process postulated here, where relentless mutation in cancer cells
results in either mutational inactivation of genes or positive selection to maintain their
function gives a functional explanation for why more advanced cancers invariably show
what pathologists refer to as “de-differentiation”; as Mueller’s ratchet [25] removes all
but the reproductively essential genes.
It will be obvious that the ability of gene sequences to display evidence of natural se-
lection is based both on a high cancer cell mutation rate and an increased cancer cell
proliferative rate which together provide the raw material on which selection can act.
As these conditions likely are greater in more advanced cancers, we would expect to
see greater molecular evidence of selection in later stage cancer cells. Indeed, compari-
son of early and later stage cancer cells could provide a roadmap of when particular
genes experience selection pressure and therefore when these genes are important for
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expected to persist for many generations of cancer cells, late stage cancers would be
expected to contain a molecular record of genes conserved at essentially any stage of
the clonal evolution of the cancer cell, even if that gene is no longer under selection
pressure or even is no longer functional. By this line of reasoning, genes which are epi-
genetically silenced would be shielded from selection and may be expected to even-
tually be subject to loss of function mutations, even if they maintain molecular
evidence of prior natural selection during tumorigenesis.
We caution that our results with regards to specific genes should be interpreted as
preliminary only. Our sample was based only on publicly available sequences and
encompassed a number of different malignancies making any conclusions about gene
function based on these findings premature. Furthermore, this approach may not dis-
tinguish between driver genes which promote oncogenesis and non-driver genes never-
theless essential for cancer cell growth and reproduction. However, the application of
previously described methods could be used to distinguish these [16,17].
As new databases of cancer genomes become available [14,17-27], a future direction for
this work will be to apply these techniques to whole genome sequences of cancer cells.
This could be performed at the level of the tumour as a whole to look at genes important
across a sample of tumours of the same type or it could be applied to single cells to ex-
plore the genes of importance in particular microenvironments such as metastatic depo-
sits. This approach, combined with oncogenetic reconstruction of cancer clonal lineages
using the same sequencing data could provide a powerful new tool to identify candidate
genes of functional significance for potential targeted therapies as well as providing new
insights into the evolutionary mechanisms of cancer cell clonal evolution.
Conclusions
Genes may be under different selection pressures within a cancer as compared to normal
tissues. In this paper we proposed a method to answer the question of what genes are im-
portant to a cancer cell. The high mutation rates and rapid cell division present in cancer
suggests that functionally important genes will show evidence of selection. We could there-
fore, in an indirect manner, observe what genes a cancer cell needs to survive. The genes
that are important could then form a list of possible targets for therapeutic intervention.
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